BR112015031277A2 - Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos - Google Patents

Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos

Info

Publication number
BR112015031277A2
BR112015031277A2 BR112015031277A BR112015031277A BR112015031277A2 BR 112015031277 A2 BR112015031277 A2 BR 112015031277A2 BR 112015031277 A BR112015031277 A BR 112015031277A BR 112015031277 A BR112015031277 A BR 112015031277A BR 112015031277 A2 BR112015031277 A2 BR 112015031277A2
Authority
BR
Brazil
Prior art keywords
polypeptides
insulin
methods
pharmaceutical compositions
stabilized
Prior art date
Application number
BR112015031277A
Other languages
English (en)
Inventor
L Verdine Gregory
HILINSKI Gerard
Yue Liang Rebecca
Alice Nagel Yvonne
Zhou Minyun
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112015031277A2 publication Critical patent/BR112015031277A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

MODULADORES DO RECEPTOR DE INSULINA DE POLIPEPTÍDEOS ESTABILIZADOS, ANÁLOGOS DE INSULINA, COMPOSIÇÕES FARMACÊUTICAS COMPREENDENDO OS REFERIDOS POLIPEPTÍDEOS E MÉTODOS DE PREPARAÇÃO E USOS DOS MESMOS. São fornecidos aqui polipeptídeos (ALFA)-CT estabilizados que compreende um segmento alfa-helicoidal e em que o polipeptídeo é de Fórmula (I-1) ou Fórmula (I-2): Rf-[XAA]s-XA1-XA2-XA3-XA4-XA5-XA6-XA7-XA8-XA9-XA10-XA11-XA12-XA13-XA14-[XAA]t-Re (I-1) Rf-[XAA]s-XC1-XC2-XC3-XC4-XC5-XC6-XC7-XC8-XC9-XC10-XC11-XC12-XC13-XC14- XC15-XC16-XC17- XC18-XC19-XC20-[XAA]t-Re (I-2) em que o polipeptídeo Alfa-CT se liga ao receptor de insulina e em que o polipeptídeo Alfa-CT inclui pelo menos um grampo (isto é, dois aminoácidos com ligação cruzada) e/ou pelo menos uma costura (isto é, três aminoácidos com ligação cruzada). São ainda fornecidos análogos de insulina que incluem os polipeptídeos Alfa-CT grampeados ou costurados, composições farmacêuticas dos mesmos, métodos de uso, por exemplo, métodos de tratamento de uma condição diabética ou complicações da mesma.
BR112015031277A 2013-06-14 2014-06-13 Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos BR112015031277A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361835242P 2013-06-14 2013-06-14
PCT/US2014/042329 WO2014201370A1 (en) 2013-06-14 2014-06-13 Stabilized polypeptide insulin receptor modulators

Publications (1)

Publication Number Publication Date
BR112015031277A2 true BR112015031277A2 (pt) 2017-09-19

Family

ID=51134430

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015031277A BR112015031277A2 (pt) 2013-06-14 2014-06-13 Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos

Country Status (12)

Country Link
US (1) US10227390B2 (pt)
EP (1) EP3008081B1 (pt)
JP (1) JP2016523241A (pt)
KR (1) KR20160019547A (pt)
CN (1) CN105492460A (pt)
AU (2) AU2014278005B2 (pt)
BR (1) BR112015031277A2 (pt)
CA (1) CA2915354A1 (pt)
HK (1) HK1223945A1 (pt)
IL (1) IL243088B (pt)
MX (1) MX2015017274A (pt)
WO (1) WO2014201370A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
ES2430067T3 (es) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US8927500B2 (en) 2012-02-15 2015-01-06 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
JP2017533889A (ja) 2014-09-24 2017-11-16 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
CA2979847A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN116874584A (zh) * 2016-07-22 2023-10-13 犹他大学研究基金会 胰岛素类似物
KR102003904B1 (ko) * 2016-08-17 2019-07-25 연세대학교 산학협력단 안정화된 알파-헬릭스 이차 구조를 갖는 펩타이드-고분자 결합체 제조방법 및 이를 이용해 제조된 펩타이드-고분자 결합체
JP7291327B2 (ja) * 2017-07-19 2023-06-15 国立大学法人徳島大学 ペプチド誘導体及びそれを含む医薬組成物
CA3074838A1 (en) 2017-09-07 2019-03-14 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
US11496462B2 (en) * 2017-11-29 2022-11-08 Jpmorgan Chase Bank, N.A. Secure multifactor authentication with push authentication
US11345725B2 (en) 2019-09-16 2022-05-31 Research Foundation Of The City University Of New York Bis-thioether stapled peptides as inhibitors of PRC2 function
US20230174576A1 (en) * 2020-10-30 2023-06-08 Xeno-Interface Inc. Beta-strand bridge peptide
CN113527416A (zh) * 2021-08-11 2021-10-22 南开大学 一种硝基还原酶响应氨基酸及肿瘤乏氧荧光探针的制备方法

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
DE68929151T2 (de) 1988-10-28 2000-07-20 Genentech Inc Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
WO1996004289A1 (en) 1992-04-03 1996-02-15 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
JP3817739B2 (ja) 1994-12-29 2006-09-06 マサチューセッツ・インスティテュート・オブ・テクノロジー キメラｄｎａ結合性タンパク質
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
EP0832096B1 (en) 1995-05-04 2001-07-18 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
EP0880357A4 (en) 1996-01-17 1999-05-12 California Inst Of Techn SYNTHESIS OF CONFORMATORICALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS BY CATALYTIC RINGCLOSE METATHESIS
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
JP2001504831A (ja) 1996-11-21 2001-04-10 プロメガ・コーポレーション アルキルペプチドアミドおよび適用
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2304124A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Bci-2-like protein bim and methods of use thereof
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
WO1999034833A1 (en) 1998-01-07 1999-07-15 Shearwater Polymers, Incorporated Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US20030190368A1 (en) 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
TR200102765T2 (tr) 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
ATE513056T1 (de) 1999-10-15 2011-07-15 Avatar Medical L L C Stabilisierte proteine
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
WO2002064790A2 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
EP1469871A4 (en) 2001-12-31 2006-08-23 Dana Farber Cancer Inst Inc METHOD FOR TREATING APOPTOSIS AND COMPOSITIONS THEREFOR
ATE394674T1 (de) 2002-04-22 2008-05-15 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
ATE377419T1 (de) 2002-11-08 2007-11-15 Hoffmann La Roche Substituierte 4-alkoxyoxazol derivate als ppar agonisten
US20070032417A1 (en) 2002-12-24 2007-02-08 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
CA2522561C (en) 2003-04-18 2012-07-17 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
JP2007537989A (ja) 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド
DK1680443T5 (en) 2003-11-05 2015-02-02 Dana Farber Cancer Inst Inc Stabilized alpha-helix peptides and uses thereof
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
EP1737884B1 (en) 2004-03-19 2016-10-19 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US7202332B2 (en) 2004-05-27 2007-04-10 New York University Methods for preparing internally constrained peptides and peptidomimetics
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
WO2006017913A1 (en) 2004-08-20 2006-02-23 Phylogica Limited Peptide inhibitors of c-jun dimerization and uses thereof
US20100298213A1 (en) * 2004-08-20 2010-11-25 Novo Nordisk A/S Pharmaceutically Active Insulin Receptor-Modulating Molecules
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2007013050A1 (en) 2005-07-25 2007-02-01 Hadasit Medical Research Services & Development Ltd. Heparanase-derived peptide dimers and their uses as inhibitors of heparanase
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
AU2007319193A1 (en) 2006-11-15 2008-05-22 Dana-Farber Cancer Institute, Inc. Stabilized MAML peptides and uses thereof
JP5656407B2 (ja) 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド ビス−スルフヒドリル大環状化系
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
PT2118123E (pt) 2007-01-31 2016-02-10 Harvard College Péptidos de p53 estabilizados e suas utilizações
EP2114428B1 (en) 2007-02-23 2012-10-31 Aileron Therapeutics, Inc. Triazole linked macrocyclic peptides
ES2430067T3 (es) * 2007-03-28 2013-11-18 President And Fellows Of Harvard College Polipéptidos cosidos
US20100273722A1 (en) 2007-08-06 2010-10-28 Yale University Modified miniature proteins
EP2208061B1 (en) 2007-09-26 2017-11-08 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
CA2971794C (en) 2007-10-04 2020-03-24 Zymogenetics, Inc. B7 family member zb7h6 and related compositions and methods
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
EP2356139A4 (en) * 2008-07-23 2013-01-09 Harvard College LIGATURE OF STAPLED POLYPEPTIDES
WO2010034029A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0918948A2 (pt) 2008-09-22 2015-12-15 Aileron Therapeutics Inc macrociclos peptidomiméticos
AU2009302385B2 (en) 2008-10-07 2015-12-03 President And Fellows Of Harvard College Telomerase inhibitors and methods of use thereof
JP2012509902A (ja) 2008-11-24 2012-04-26 エルロン・セラピューティクス・インコーポレイテッド 改善された特性を有するペプチド模倣大環状分子
UA91281C2 (ru) 2008-11-26 2010-07-12 Общество С Ограниченной Ответственностью «Мако» Способ получения рекомбинантного инсулина человека
EP2358748B1 (en) 2008-12-09 2016-07-06 Dana-Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
CA2746265A1 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
EP2422201B1 (en) * 2009-04-22 2015-04-22 The Walter and Eliza Hall Institute of Medical Research Structure of the c-terminal region of the insulin receptor alpha -chain and of the insulin-like growth factor receptor alpha -chain
BR112012000867A2 (pt) 2009-07-13 2019-09-24 Harvard College "polipeptídeos bifuncional costurado e uso do mesmo"
EP2488193A4 (en) 2009-10-14 2013-07-03 Aileron Therapeutics Inc IMPROVED PEPTIDOMIMETIC MACROCYCLES
WO2011146974A1 (en) 2010-05-25 2011-12-01 Monash University Methods for the synthesis of alkyne-containing dicarba bridges in peptides
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
WO2012040459A2 (en) 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012065181A2 (en) 2010-11-12 2012-05-18 Dana Farber Cancer Institute, Inc. Cancer therapies and diagnostics
JP2014520120A (ja) 2011-06-17 2014-08-21 プレジデント アンド フェローズ オブ ハーバード カレッジ 安定化した変異型ｍａｍｌペプチドおよびその使用
WO2012174423A1 (en) 2011-06-17 2012-12-20 President And Fellows Of Harvard College Stabilized polypeptides as regulators of rab gtpase function
AU2013325099B2 (en) * 2012-09-25 2018-11-15 The Walter And Eliza Hall Institute Of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
JP6506166B2 (ja) 2012-09-26 2019-04-24 プレジデント アンド フェローズ オブ ハーバード カレッジ プロリンロックドステープルドペプチドおよびその用途
WO2014055564A1 (en) * 2012-10-01 2014-04-10 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
WO2014110420A1 (en) 2013-01-10 2014-07-17 Noliva Therapeutics Llc Peptidomimetic compounds
US10081654B2 (en) * 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof

Also Published As

Publication number Publication date
EP3008081B1 (en) 2017-08-30
EP3008081A1 (en) 2016-04-20
MX2015017274A (es) 2016-08-04
HK1223945A1 (zh) 2017-08-11
WO2014201370A1 (en) 2014-12-18
US20160215036A1 (en) 2016-07-28
US10227390B2 (en) 2019-03-12
AU2014278005B2 (en) 2018-11-22
AU2019201247A1 (en) 2019-03-14
CN105492460A (zh) 2016-04-13
JP2016523241A (ja) 2016-08-08
IL243088B (en) 2018-12-31
KR20160019547A (ko) 2016-02-19
CA2915354A1 (en) 2014-12-18
AU2014278005A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
BR112015031277A2 (pt) Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
BR112015032875A2 (pt) derivados de peptídeos do tipo glp-1, e usos dos mesmos
BR112018073511A2 (pt) polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
BR112018012794A2 (pt) receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr
BR112019010699A2 (pt) receptores de células t e imunoterapia empregando os mesmos
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
CL2015002940A1 (es) Usos terapéuticos de empaglifozina.
BR112016013138A2 (pt) mistura de peptídeos
BR112014017165A8 (pt) polipeptídeos de fator quimérico viii e seus usos
BR112016028835A2 (pt) derivados de auristatina e conjugados dos mesmos
AR098736A1 (es) Análogos del péptido exendina-4 como agonistas duales del receptor del glp-1 / gip (péptido similar al glucagón tipo 1 / polipéptido insulinotrópico dependiente de glucosa)
BR112017008157A2 (pt) polipeptídeos de fgf-21 modificados e usos dos mesmos
BR112016016578A2 (pt) Insulina de ação prolongada e uso daanálogo de insulina, polinucleotídeo, vetor de expressão, transformante, insulina de ação prolongada bem como seu método de preparação e formulação da mesma, conjugado, e uso do mesmo mesma
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
BR112019023337A2 (pt) Ligase engenheirada, sequência de polinucleotídeo, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da ligase engenheirada, um produto de ligação, uma biblioteca de dna e uma pluralidade de fragmentos de dna adequados para sequenciamento, e, composição
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
BR112016014810A2 (pt) Antagonistas de fcrn e métodos de uso
BR112018075396A2 (pt) anticorpo neutralizante contra dengue para uso em um método de prevenção e/ou tratamento de infecção por zika
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
BR112013008407A2 (pt) antígenos de clostridium difficile
BR112016001036A2 (pt) fusocinas envolvendo citocinas com afinidades de ligação de receptores fortemente reduzida
BR112018007154A2 (pt) polipeptídeo de ligação a pd-l1, proteína de fusão ou conjugado, complexo, polinucleotídeo, e composição
BR112019004770A2 (pt) anticorpos do vírus antidengue, polipeptídeos contendo regiões fc variantes, e métodos de uso

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements